Featured Research

from universities, journals, and other organizations

Anti-inflammatory Drug Prevents Liver Cancer In At-risk Liver Patients

Date:
September 11, 2006
Source:
John Wiley & Sons, Inc.
Summary:
Colchicine, an anti-inflammatory drug most often used to treat gout, prevented liver cancer in patients with hepatitis virus-related end-stage liver disease, according to a new study.

Colchicine, an anti-inflammatory drug most often used to treat gout, prevented liver cancer in patients with hepatitis virus-related end-stage liver disease, according to a new study. Published in the October 15, 2006 issue of CANCER, a peer-reviewed journal of the American Cancer Society, the study found that over three years of follow-up, patients with viral cirrhosis treated with colchicine were significantly less likely to be diagnosed with hepatocellular carcinoma (HCC) than those who did not receive the treatment, and significantly delayed the onset of HCC in patients who did develop the disease.

HCC is the fifth leading cancer worldwide and causes over 1 million deaths per year. The primary risk factor for HCC is fibrotic liver disease, or cirrhosis. Hepatitis viruses B and C are also major risk factors, as are metabolic diseases that affect the liver. Liver disease has a wide clinical spectrum, from mild abnormal lab results to irreversible fibrosis of the liver. Much of the damage to the liver is caused by inflammation, which can be caused by acute or chronic toxin exposure or infection. Inflammation is also implicated in the progression of HCC.

Colchicine is an anti-inflammatory drug commonly used to treat diseases such as gout and psoriasis. Animal studies have found that it also inhibits fibrosis formation in the liver. However, human trials on patients with liver cirrhosis demonstrated no significant efficacy in liver disease progression. Its effect on HCC prevention and progression has never been studied.

Led by Oscar Arrieta, M.D. of the Instituto Nacional de Cancerologνa in Mexico City, researchers evaluated colchicine as a drug to prevent HCC in patients with liver cirrhosis. They reviewed data from 186 patients with cirrhosis of the liver due to viral disease, of whom 116 were treated with colchicine.

They found that only about one in ten (9 percent) of patients treated with colchicine developed HCC compared to more than one in four (29 percent) of untreated cirrhotic patients. In addition, if subjects developed HCC, patients who were treated with colchicine developed HCC later than those not treated with the drug. Colchicine chemoprevention delayed the diagnosis of HCC after cirrhosis onset by an average 72 months (222 months compared to 150 months). Furthermore, colchicine-treated patients survived longer than untreated patients.

These findings, according to the authors, "demonstrate that colchicine can prevent the development of HCC, independently from other factors such as age, platelet count, alpha-FP and transaminase levels."


Story Source:

The above story is based on materials provided by John Wiley & Sons, Inc.. Note: Materials may be edited for content and length.


Cite This Page:

John Wiley & Sons, Inc.. "Anti-inflammatory Drug Prevents Liver Cancer In At-risk Liver Patients." ScienceDaily. ScienceDaily, 11 September 2006. <www.sciencedaily.com/releases/2006/09/060911013549.htm>.
John Wiley & Sons, Inc.. (2006, September 11). Anti-inflammatory Drug Prevents Liver Cancer In At-risk Liver Patients. ScienceDaily. Retrieved September 21, 2014 from www.sciencedaily.com/releases/2006/09/060911013549.htm
John Wiley & Sons, Inc.. "Anti-inflammatory Drug Prevents Liver Cancer In At-risk Liver Patients." ScienceDaily. www.sciencedaily.com/releases/2006/09/060911013549.htm (accessed September 21, 2014).

Share This



More Health & Medicine News

Sunday, September 21, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Sierra Leone in Lockdown to Control Ebola

Sierra Leone in Lockdown to Control Ebola

AP (Sep. 21, 2014) — Sierra Leone residents remained in lockdown on Saturday as part of a massive effort to confine millions of people to their homes in a bid to stem the biggest Ebola outbreak in history. (Sept. 20) Video provided by AP
Powered by NewsLook.com
Sierra Leone's Nationwide Ebola Curfew Underway

Sierra Leone's Nationwide Ebola Curfew Underway

Newsy (Sep. 20, 2014) — Sierra Leone is locked down as aid workers and volunteers look for new cases of Ebola. Video provided by Newsy
Powered by NewsLook.com
Changes Found In Brain After One Dose Of Antidepressants

Changes Found In Brain After One Dose Of Antidepressants

Newsy (Sep. 19, 2014) — A study suggest antidepressants can kick in much sooner than previously thought. Video provided by Newsy
Powered by NewsLook.com
Could Grief Affect The Immune Systems Of Senior Citizens?

Could Grief Affect The Immune Systems Of Senior Citizens?

Newsy (Sep. 19, 2014) — The study found elderly people are much more likely to become susceptible to infection than younger adults going though a similar situation. Video provided by Newsy
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
 
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:  

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:  

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile iPhone Android Web
Follow Facebook Twitter Google+
Subscribe RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins